Loading…
Loading grant details…
| Funder | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES |
|---|---|
| Recipient Organization | Children'S Hosp of Philadelphia |
| Country | United States |
| Start Date | Aug 27, 2021 |
| End Date | May 31, 2025 |
| Duration | 1,373 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | NIH (US) |
| Grant ID | 10850960 |
Project Summary: Our goal is to improve the lives of children with Hirschsprung disease (HSCR), a life- threatening birth defect where the enteric nervous system (ENS) is absent from the end of the bowel. Because the ENS regulates most aspects of bowel function, “aganglionic” bowel that lacks ENS does not work well.
Symptoms include intractable constipation, bilious vomiting, abdominal distension, growth failure and HSCR- associated enterocolitis (HAEC). HAEC is the most dangerous problem because in addition to bowel inflammation, during HAEC, bacteria may move across the bowel epithelium causing sepsis that can be fatal.
Primary treatment for HSCR is pull-through surgery to remove aganglionic bowel and re-attach ENS-containing bowel to near the anal verge. Unfortunately, ~35% of children continue to have problems after pull-through surgery, including HAEC. One long-standing mystery is why symptom onset and severity differ so much among
children with HSCR. In particular, some children never have HAEC, but other children have repeated HAEC episodes before and after pull-through surgery. Length of aganglionosis, genetic differences, and surgical details undoubtedly impact HAEC risk and HSCR outcomes. The impact of non-genetic factors like diet, gut microbes
and small molecules inside the bowel have barely been investigated in HSCR or in HSCR models. Using Piebald lethal sl/sl mice, a well-established HSCR model, we discovered a 5-fold difference in survival between two mouse facilities. The survival difference is not related to the length of aganglionic bowel, distinct genetics, or
cause of death, and we do not perform surgery. Instead, the survival difference reflects fundamental aspects of HSCR pathophysiology that can be altered by non-genetic factors in the environment. We hypothesized that the 5-fold survival difference occurs because sl/sl mice are fed different types of food and have different bowel
microbes at each institution. Differences in diet and gut microbes can alter small molecules within the bowel. Many small molecules including nutrients in food and microbial metabolites impact bowel barrier function in ways that affect sepsis risk. Aim 1 tests the hypothesis that diet and microbes affect survival by swapping diets fed to
sl/sl at each institution, making germ-free mice, and performing fecal transplant into germ-free mice using stool from each institution. New preliminary data suggest that simply changing diet markedly alters survival in sl/sl mice. Aim 2 defines how the bowel barrier differs in sl/sl between institutions using anatomic and functional
approaches and identifies microbes that cross bowel epithelium to cause sepsis. Aim 3 defines mucosa- associated microbes and small molecules within the bowel lumen that could affect barrier function. At the completion of this study we will know if diet or gut microbes can be manipulated to improve survival in HSCR
models and will have defined mechanisms that alter sepsis risk. These data can then be leveraged to design human clinical trials to improve outcomes in children with HSCR and reduce HAEC occurrence.
Children'S Hosp of Philadelphia
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant